Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Read More
Tag: DUB
Almac links with MSD in research collaboration
Almac and MSD will initially work together in a two-year joint research programme
Read More
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
